T cell reactivity to Sjögren's syndrome related antigen La(SSB).
OBJECTIVE
Many patients with primary Sjögren's syndrome (SS) make high titer IgG autoantibodies to the La(SSB) antigen, suggesting antigen specific T cell-B cell interactions. T cell responses to some nuclear antigens, particularly U1RNP, have been detected in patients with systemic lupus erythematosus (SLE) and in healthy subjects. We investigated T cell reactivity to the autoantigen SSB in patients with SS and healthy controls.


METHODS
Using the [3H]thymidine proliferation assay, we determined reactivity to purified recombinant SSB (rSSB) in 20 patients with SS and 19 controls. Specificity was determined using tetanus toxoid, endotoxin, and 3 other autoantigens (PBC.M2, Sc170, and GAD). Precursor frequency was calculated by limiting dilution analysis. HLA Class II dependency was investigated using anti-Class II monoclonal antibodies. HLA-DR typing was by polymerase chain reaction and sequence specific oligonucleotide typing.


RESULTS
Six of 20 patients with SS and 10/19 controls proliferated to La(rSSB). Precursor frequency of anti-SSB T cells was 1:77,040 and 1:115,000 in 2 healthy subjects and 1:230,250 and 1:103,034 in two patients with SS. Anti-HLA-DR abrogated proliferation to SSB and tetanus toxoid. Thirteen of 15 patients with SS and 4/17 controls were HLA-DR3 positive, with no apparent association of HLA-DR3 with SSB reactivity in controls.


CONCLUSIONS
Anti-La(SSB) specific T cells occur in a significant proportion of controls and in some patients with SS. The function of SSB T cells in controls remains to be defined. They may represent immunoregulatory cells, and further analysis of these cells, and a comparison to those found in patients with SS, may elucidate normal immunoregulation and the derangements that lead to Sjögren's syndrome.
Helsloot
J
J
Rheumatology Department, St. George Hospital, Sydney, NSW, Australia.
Sturgess
A
A
D000328:Adult; D000368:Aged; D000918:Antibody Specificity; D001323:Autoantibodies / Q000032:analysis; D001324:Autoantigens / Q000276:immunology* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D004731:Endotoxins / Q000276:immunology / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D012261:Ribonucleoproteins / Q000276:immunology* / Q000494:pharmacology; D012859:Sjogren's Syndrome / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology / Q000494:pharmacology; D014157:Transcription Factors / Q000276:immunology; D000097585:SS-B Antigen
D001323:Autoantibodies; D001324:Autoantigens; D004731:Endotoxins; D000939:Epitopes; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D012261:Ribonucleoproteins; D013745:Tetanus Toxoid; D014157:Transcription Factors; D000097585:SS-B Antigen